Seite 9 von 11
Neuester Beitrag: 29.04.21 15:48
|Eröffnet am:||20.02.10 14:37||von: Andreano||Anzahl Beiträge:||273|
|Neuester Beitrag:||29.04.21 15:48||von: Vassago||Leser gesamt:||55.540|
|Seite: < 1 | ... | 5 | 6 | 7 | 8 | | 10 | 11 >|
in die richtige Richtung zu gehen...zudem ist Celldex jetzt gut finanziert.:-)
Unternehmen und günstig bewertet:
- Infos zur Bilanz: Verlust i´n Q1/2012 = 13 Mio USD + 92,4 MioUSD Cash, d.h. bestens finanziert für noch 2 Jahre
- Pipeline (nur die zwei wichtigsten):
CDX-110: Vaccine for EGFRvIII-expressing tumors = ist eine Immunotherapie die gegen EGFRvIII gerichtet ist, eine Mutation des epidermal growth factor receptor (EGFR und vailidertes Target in der Krebstherapie. EGFRvIII wird in gesundem Gewebe kaum gefunden, d.h. gesundes Gewebe sollte bei einer Theraopie kaum betroiffen sein. Zellen, die EGFRvII exprimieren, haben eine hööhere Wahrscheinlichkeit des unreguliertes Wachstums. CDX-110 aktiviert das menschluiche Immunsystem gegen Tumrozellen, die EGFRvIII exptrimieren.
"... the initial results from CDX-110 in the treatment of glioblastoma multiforme are encouraging, with an overall survival (OS) of 24.6 months compared to 15.2 months (historical cohort)."
CDX-011: "Preliminary results suggest that CDX-011 induces impressive response rates compared to current, available therapies in patients with advanced, refractory breast cancers with high GPNMB expression (expression in ≥25% of tumor cells). In this high expressing patient population, treatment with CDX-011 resulted in a 32% overall response rate (ORR; includes confirmed and unconfirmed responses), whereas treatment with Investigator's Choice (IC) single-agent chemotherapy resulted in a 13% ORR. CDX-011 also demonstrated strong response rates in patients with triple negative breast cancer across all levels of GPNMB expression (CDX-011 ORR of 21%; IC ORR of 0%), where treatment options are extremely limited. In addition, in patients with triple negative breast cancer who also highly express GPNMB, greater activity was observed (CDX-011 ORR of 36%; IC ORR of 0%). The ORR across all levels of GPNMB expression was 19% for the CDX-011 arm and 14% for the IC arm, and a direct, positive correlation was observed between increasing levels of GPNMB expression and increased CDX-011 response rates. Based on these data, the Company believes CDX-011 has significant promise as a targeted therapy for patients with breast cancer and high expression of GPNMB, and especially for those with triple negative disease."
...und das Beste ist, der Laden wird erst mit 235 Mio Euro bewertet.:.-)
CDX-1401 - Clinical Program in NY-ESO-1 Expressing Malignancies
Our second APC Targeting Technology™ product candidate, CDX-1401, is in Phase 1/2 development for the treatment of cancers known to express NY-ESO-1, including cancers of the bladder, breast, ovary, non-small cell lung cancer, myeloma, sarcoma and melanoma. This product is intended to selectively deliver the NY-ESO-1 antigen to Antigen-Presenting Cells (APCs) for generating robust immune responses against cancer cells expressing NY-ESO-1. Initial data from this ongoing study confirm safety and immunogenicity even in patients with advanced cancer who have received multiple prior therapies.
CDX-1127 - Clinical Program for Hematologic Malignancies and Solid Tumors
CDX-1127 is an agonist anti-CD27 monoclonal antibody (mAb) that is expected to activate CD27 expressing T cells in the context of T cell receptor stimulation. In addition to the immune enhancing properties of CDX-1127, the mAb may also provide direct therapeutic effects against tumors with CD27 expression. CDX-1127 is in Phase 1 development for the treatment of B cell hematologic malignancies known to express CD27 including, but not limited to, chronic lymphocytic leukemia (CLL), Burkett’s lymphoma, mantle cell lymphoma, primary lymphoma of the central nervous system and marginal zone B-cell lymphoma and solid tumors that may be more likely to be sensitive to immune therapy: metastatic melanoma, renal cell carcinoma, hormone-refractory prostate adenocarcinoma, ovarian cancer, colorectal adenocarcinoma or non-small cell lung cancer (NSCLC).
DCVax-001 – HIV Vaccine: Celldex and Rockefeller University investigators are collaborating on an effort to develop a vaccine against HIV, the virus known to cause AIDS. The Rockefeller vaccine, called DCVax-001, is an APC-targeted vaccine consisting of a fusion protein of a human monoclonal antibody with specificity for the dendritic cell receptor, DEC-205 linked to an HIV antigen. This program has been funded through a grant from the Bill & Melinda Gates Foundation. The vaccine is currently being tested in a Phase 1 trial in healthy volunteers at Rockefeller University
CDX-1135 – Renal Disease: Celldex is developing soluble Complement Receptor Type 1 (sCR1, TP10), a specific and potent inhibitor of complement activation, for use in renal disease indications. sCR1 has previously been in clinical trials and demonstrated a good safety profile and complement inhibition. sCR1 inhibits the classical, alternative and lectin pathways of complement at both early (C3 convertase) and late (C5 convertase) stages by down-regulating the activation of these cascades. sCR1 affects only activated complement and is not consumed, but can recycle in the inhibitory process. Certain rare renal diseases involve dysregulated complement and have been associated with mutations in complement proteins including Factor H and Membrane Cofactor Protein (MCP). sCR1 has similarities to Factor H and MCP in structure and function, thus providing strong support for its potential efficacy in these diseases.
CDX-1189 - Renal Disease: Celldex is developing therapeutic human antibodies to a signaling molecule known as CD89 or Fcα receptor type I (FcαRI). CD89 is expressed by some white blood cells and leukemic cell lines, and has been shown to be important in controlling inflammation and tumor growth in animal models. Celldex has proprietary, fully human antibodies to CD89 in preclinical development. Depending upon the specific antibody used, anti-CD89 antibodies can either be activating and thus stimulate immune responses, or down-regulating and anti-inflammatory.
Celldex hat ganz schön viele Aktivitäten laufen - viele im Bereich der Immunotherapie. Am interessantesten sind natürlich die weiter fortgeschrittenen Programme Phase III gegen eine besonders bösartige Form des Hirnturmos (glioblastoma) und das Phase IIb Programm (CDX-011 is a fully-human monoclonal antibody-drug conjugate (ADC) gegen Brustkrebs. In beiden Fällen gibt es bereits vielversprechende klinische Daten.